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Abstract
Introduction: The Molecular Adsorbent Recycling System (MARS) is used to treat patients with liver failure.
Observational data suggest that citrate anticoagulation during MARS is feasible. Comparative studies on the
optimal anticoagulation regimen during MARS are lacking. The aim of the current study was to evaluate two
heparin-free anticoagulation regimens.
Methods: We performed a prospective randomized open-label crossover study of regional citrate anticoagulation
against no anticoagulation. Ten patients (age 55 ± 11 years) with liver failure undergoing MARS treatment were
included. The primary endpoint was completion of MARS sessions. Secondary endpoints included treatment
efficacy and safety. Longevity of MARS treatment was plotted as a Kaplan-Meier estimate. Fisher’s exact test was
used for contingency table analysis.
Results: Of a total of 27 6-hour sessions, four sessions had to be terminated prematurely, three due to occlusive
clotting of the extracorporeal circuit and one due to uncontrollable bleeding from the vascular access site. All four
events occurred in the group without anticoagulation. Between group comparison demonstrated citrate
anticoagulation to significantly increase the likelihood of completed MARS treatment (Fisher’s exact test, P 0.04).
This translates into higher bilirubin reduction ratios when citrate was applied (reduction ratio 0.25 vs. 0.15, P 0.02).
Systemic ionized calcium concentrations were significantly reduced during citrate anticoagulation (P < 0.001) but
remained within a safe range. We observed no major adverse events.
Conclusions: Regional citrate anticoagulation in patients with liver failure is feasible. Citrate anticoagulation
provides superior patency of the extracorporeal circuit. Avoidance of anticoagulation during MARS results in
significant loss of treatment efficacy, due to treatment downtime. Additional studies are required to identify the
optimal anticoagulation regimen for extracorporeal circulation in patients with liver failure.
Introduction
Liver failure, whether acute, acute-on-chronic or end-
stage liver insufficiency, remains an important cause of
morbidity and mortality. The lack of liver detoxification
as well as the loss of metabolic and regulatory functions
of the liver leads to life-threatening complications,
including renal failure, altered immune response, hepatic
coma and systemic hemodynamic dysfunction,
eventually culminating in multi-organ failure. Current
medical therapy involves the management of the preci-
pitating event and treatment of complications until the
liver eventually recovers, leaving us with no other treat-
ment options other than transplantation if these
attempts fail [1].
During the acute phase of their disease, a substantial
number of patients are treated using extracorporeal
blood purification devices. Besides regular hemodialysis,
the Molecular Adsorbent Recycling System (MARS,
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Gambro AB, Lund, Sweden) is used with increasing fre-
quency. This non-biologic liver dialysis system is cur-
rently in use to bridge patients with acute liver failure
and acute-on-chronic liver failure, either to recovery of
native liver function or to liver transplantation [2].
Liver failure is characterized by a balanced but brittle
coagulation system. Minor disturbances profoundly
increase the risks of severe bleeding and of thrombotic
events [3]. An important area of debate at present is the
choice of the optimal extracorporeal blood circuit antic-
oagulation regimen. On the one hand, systemic anticoa-
gulation therapy should be minimized given the high
risk of bleeding associated with liver failure. On the
other hand, contact of blood with the extracorporeal cir-
cuit leads to coagulation activation and might result in
loss of coagulation factors, contributing to broad coagu-
lation disturbances [4].
Unfractionated heparin and to a lesser extent low
molecular weight heparin are the standard of care antic-
oagulation regimens in most centers. However, optimal
dosage has not been studied. Moreover, heparin induces
systemic anticoagulation, thereby aggravating liver fail-
ure-associated coagulopathy. Several retrospective stu-
dies reported on protocols to minimize heparin
anticoagulation during MARS dialysis. Faybik et al.
reported on the use of prostaglandin I2 during MARS
treatment. However, in this cohort, half of the patients
still received additional unfractionated heparin [5]. Sev-
eral retrospective studies suggested the feasibility of
MARS without anticoagulation [6-10]. All of these stu-
dies reported clotting of the extracorporeal circuit and/
or severe coagulopathy due to contact activation in a
subset of treatments (Table 1).
Regional citrate anticoagulation might provide suffi-
cient anticoagulation of the extracorporeal blood circuit,
thus minimizing contact activation-associated coagulo-
pathy, while maintaining systemic coagulation [11,12].
Regional citrate anticoagulation for regular hemodialysis
is feasible, well-tolerated and safe [11]. In contrast,
experience with citrate anticoagulation during treatment
of patients with liver failure is limited. The liver contri-
butes substantially to exogenous citrate metabolism and
endogenous citrate clearance in patients with liver fail-
ure is reduced [13]. In an observational non-comparative
study, regional citrate anticoagulation was used during
50 consecutive liver dialysis treatments using the fractio-
nated plasma separation and adsorption system (FPSA,
Prometheus®). Substantial clotting of the dialyser
occurred only twice [14]. More recently, Faybik et al.
performed a prospective observational study in twenty
patients treated with MARS. Regional citrate anticoagu-
lation appeared safe with superior patency of the extra-
corporeal circuit during treatment [15], but further
studies are required to support widespread application
of citrate anticoagulation during MARS treatment [16].
Little evidence thus supports choice of the optimal
anticoagulation regimen during MARS. The aims of this
prospective cross-over study in patients with acute-on-
chronic liver failure were (A) to investigate feasibility of
regional citrate anticoagulation during MARS and (B) to
compare biocompatibility, safety and efficacy of anticoa-




Patients with acute-on-chronic liver failure, admitted to
the medical intensive care unit, University Hospitals
Leuven, Belgium, were screened for eligibility. The diag-
nosis of liver failure was considered if patients, pre-
viously known with compensated chronic liver disease
as defined by Gines et al. [17], developed intrahepatic
cholestasis (serum bilirubin > 5 mg/dl without radiologic
evidence of extra-hepatic origin) and had at least one of
the following complications within a time span of four
to eight weeks after a potential identifiable acute super-
posed hepatic insult: a) a progressive hyperbilirubinemia
defined as a more than 50% increase of bilirubin or up
to a level of > 20 mg/dl, b) hepatic encephalopathy ≥ II,
c) de novo development of ascites, and/or d) hepatorenal
syndrome, defined according to the criteria of the Inter-
national Ascites Club which were prevalent at that time
[18]. Inclusion criteria were scheduled liver dialysis
using the MARS system and age over 18 years.
Table 1 Heparin-free MARS studies









Doria et al. (2004) retrospective AoCLF/pruritus 9 9/74 0 (0/0%) 4 (44/nd%) [6]
Tan et al. (2007)a retrospective ALF/AoCLF 4 4/12 1 (25/8%) 1 (25/8%) [8]
Bachli et al. (2007) retrospective ALF/AoCLF/pruritus 21 nd/40 nd 7 (nd/18%) [7]
Yang et al (2008)a retrospective ALF/AoCLF 10 5/13 1 (20/8%) 1 (20/8%) [9]
Tan et al. (2010)a retrospective ALF/AoCLF 12 12/44 11 (nd/25%) 4 (nd/9%) [10]
Faybik et al.(2011) Prospective ALF/AoCLF 20 20/77 1 (5/1%) 1 (5/1%) [15]
aThese papers originate from the same research group. It is unclear whether these manuscripts report on the same patient population or not. ALF, acute liver
failure; AoCLF, acute-on-chronic liver failure; MARS, Molecular Adsorbents Recirculation System; P, patients; S, sessions; nd, no data.
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Exclusion criteria were severe hypocalcemia (Ca2+ < 0.9
mmol·l-1) or acidosis (pH < 7.25) due to any cause.
Study design
This was a prospective randomized open-label double
crossover study (clinicaltrials.gov NCT00695617). The
cross-over design was chosen to minimize heterogeneity,
given that liver failure is a heterogeneous disease state
and given the low number of patients available for
enrolment.
At day 1, patients were randomized to either MARS
treatment with citrate anticoagulation (n = 5) or coagu-
lation-free MARS treatment (n = 5). At day 2, patients
were switched to the opposite anticoagulant regimen.
From day 3 and thereafter, patients received their initial
anticoagulation regimen. Randomization was by the
sealed envelope method. Written informed consent was
obtained from all patients, or in case of hepatic ence-
phalopathy, from their next of kin. The study was per-
formed according to the Declaration of Helsinki and
approved by the ethics review board of the University
Hospital Leuven.
Procedures
During MARS treatment, both water-soluble and the
free fraction of protein-bound liver toxins are dialysed
into the secondary circuit (Figure 1), while blood cells
and proteins are retained in the primary circuit. In the
secondary circuit, an albumin-rich aqueous solution
(human albumin 200 g/l, Baxter SA, Lessines, Belgium)
is regenerated over two adsorbent columns. A dialyser
in the secondary circuit permits clearance of water-solu-
ble molecules [2,19,20]. MARS treatments were deliv-
ered with a MARS monitor (Gambro AB, Lund,
Sweden) coupled to a hemodialysis device (AK200,
Gambro AB, Lund, Sweden). MARS prescription was six
consecutive hours for all procedures. The blood circuit
was primed with 5000 IE heparin (LEO pharma, Wilrijk,
Belgium). Blood access was by double lumen catheteri-
zation (Hemoaccess, Gambro-Hospal, Zaventem, Bel-
gium) of the femoral vein in all patients.
Venous blood samples for monitoring of pH and
ionized calcium concentrations were taken from the dia-
lysis tubing at sampling ports proximal and distal to
citrate infusion at start, 30, 60, 120, 240 and 360 (or end
of treatment) minutes. Samples were collected in dedi-
cated recipients (PICO50, Radiometer Copenhagen,
Brønshøj, Denmark, containing 80 IU of electrolyte-
balanced heparin) and immediately analyzed on an ABL
700 blood gas analyzer (Radiometer Copenhagen,
Brønshøj, Denmark). For validation purposes, simulta-
neous collection of venous and arterial blood samples
was performed in a subset of patients.
For citrate anticoagulation, hypertonic trisodium
citrate (1.035 M, Baxter, Lessines, Belgium) was continu-
ously infused into the afferent dialysis tubing. Citrate
flow rates, initially set at 62.1 mmol·h-1, were adapted to
maintain extracorporeal ionized calcium concentrations
measured at the dialyzer inlet between 0.20 and 0.30
mmol·l-1. The anticoagulant effect was neutralized by
dialyzing against a calcium-containing dialysate. Dialy-
sate composition was Na+ 135 mmol·l-1, K+ 3 mmol·l-1,
Ca2+ 1.5 mmol·l-1, Mg2+ 0.5 mmol·l-1, Cl- 108 mmol·l-1,
HCO3
- 25 mmol·l-1 and acetate 3 mmol·l-1. Systemic
ionized calcium concentrations and blood pH, sampled
from the afferent dialysis tubing proximal to citrate infu-
sion, were monitored at the start and at 30, 60,120, 240
and 360 minutes. Systemic ionized calcium concentra-
tions were maintained within ± 15% of baseline values.
According to a prespecified protocol, CaCl2 (10 mL, 11
mEq Ca2+, Sandoz, Lausanne, Switzerand) was adminis-
tered as an intravenous bolus injection when ionized
calcium concentrations dropped below 0.8 mmol·l-1.
During sessions without anticoagulation, dialysate
composition was Na+ 140 mmol·l-1, K+ 3 mmol·l-1, Ca2+
1.5 mmol·l-1, Mg2+ 0.5 mmol·l-1, Cl- 108 mmol·l-1,
HCO3
- 38 mmol·l-1 and acetate 3 mmol·l-1.
Outcomes
The primary endpoint was uninterrupted completion of
MARS sessions. Causes of preterm interruption of
MARS treatment, including occlusive clotting of the
extracorporeal circuit and intractable bleeding during
MARS, were prospectively recorded.
Figure 1 Schematic diagram of the Molecular Adsorbents
Recirculation System. Blood is dialysed against an albumin
containing secondary circuit. The MARS® membrane allows passage
of both water-soluble and the free fraction of protein-bound
hepatic failure related toxins. In the secondary circuit, the albumin
solution is regenerated by low-flux dialysis and passage over two
adsorbent surfaces, an activated charcoal and an anion exchanger,
respectively. For regional citrate anticoagulation, citrate is
continuously infused in the afferent blood tubing, thus reducing
ionized calcium concentrations at the MARS dialyzer inlet to 0.2 to
0.3 mmol·l-1. Restoration of blood calcium is by dialysis against
dialysate containing Ca2+ at a concentration of 1.5 mmol·l-1.
Systemic ionized calcium concentrations are repeatedly monitored
during the procedure. If systemic calcium concentration falls below
0.8 mmol·l-1 despite calcium influx through the dialysate, additional
CaCl2 is administered as an intravenous bolus injection. MARS,
Molecular Adsorbents Recirculation System.
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Secondary endpoints included a semi-quantitative dia-
lyser clotting score, which has been used previously
[11]. Coagulation studies included activated partial
thromboplastin time (aPTT), prothrombin time (PT)
measured by standard laboratory techniques and throm-
bin-antithrombin complex (TAT) formation, analyzed
by Enzygnost TAT micro kit (OWMG 15 Dade Behring,
Marburg, Germany). Treatment efficacy was defined as
reduction ratios (RR) of urea, creatinine, total bilirubin
and bile acids. RRs were calculated as RR = (Cpre-Cpost)/
Cpre , where Cpre and Cpost represent concentrations at
the start and at the end of the treatment session,
respectively.
Statistics
Continuous variables are expressed as mean (standard
deviation (SD)) for normally distributed variables or
median (interquartile range), otherwise. Due to a wide
variation in the prevalence of reported clotting and
bleeding episodes (Table 1) we did not perform formal
power calculations. The number of patients, but not of
sessions, was pre-specified (n = 10). Longevity of MARS
treatment was plotted as a Kaplan-Meier estimate. Due
to low event numbers, Fisher’s exact test was used for
contingency table analysis. For between group compari-
son of continuous variables, the Mann-Whitney-Wil-
coxon test was used. A two sided P < 0.05 was
considered significant. For statistics, SAS (version 9.1,
the SAS institute, Cary, NC, USA) and SPSS (version
15.0, Chicago, Il, USA) software packages were used.
Results
Study population
Between August 2008 and June 2009, ten patients with
acute-on-chronic liver failure, fulfilling the inclusion cri-
teria and providing informed consent, were included in
this prospective cross-over study. Baseline characteristics
and three-month patient survival are presented in Table
2. Ten patients were randomized to start with citrate
anticoagulation (n = 5) or to start with heparin-free
MARS treatment (n = 5). Eight patients received at least
one session with both anticoagulation regimens. Two
patients died between their first and second treatment
session, one treated with citrate anticoagulation, one
treated without anticoagulation. As a result, 14 six-hour
MARS sessions with regional citrate anticoagulation
were compared to 13 six-hour MARS sessions without
anticoagulation. The study included eight switches from
citrate to anticoagulation-free MARS treatment and
seven opposite switches.
Primary endpoint analysis
The primary endpoint was completion of scheduled six-
hour MARS sessions (n = 27). Regional citrate anticoa-
gulation was performed in 14 sessions; the remainder
were anticoagulation-free MARS sessions. Four sessions
were interrupted preterm, in three patients. During
three sessions, occlusive clotting of the extracorporeal
circuit occurred. One session was terminated preterm
due to uncontrollable bleeding from the vascular access
site. All events happened during anticoagulation-free
MARS treatments. Longevity of scheduled MARS ses-
sions was plotted as a Kaplan-Meier estimate (Figure 2).
Citrate anticoagulation provided significantly fewer
interruptions (Log rank, P = 0.03). Between group com-
parison demonstrated citrate anticoagulation signifi-
cantly increased the likelihood of a full six-hour session
of MARS treatment (Fisher’s exact test, P = 0.04).
Secondary endpoint analyses
Secondary endpoint analyses are reported in Table 3.
Clotting scores indicate more outspoken clotting of the
dialyser in sessions without citrate (P = 0.009), in line
with the primary endpoint of more frequently inter-
rupted MARS sessions without anticoagulation.
Although platelets were reduced after most sessions,
loss of platelets was more profound after MARS sessions
without citrate (P = 0.03). Treatment efficacy, defined as
Table 2 Patient characteristics and 3-month survival
Patient Age Etiology Child MELD Day 1 Sessions 3m survival
1 52 Alcoholic B9 22 citrate 4 deceased
2 47 Alcoholic C13 43 nil 3 deceased
3 32 Alcoholic C11 26 nil 3 transplanted, alive
4 68 Hepatitis C C11 34 citrate 2 lost to follow up
5 51 Alcoholic C10 23 nil 3 alive
6 63 Alcoholic C10 30 citrate 4 alive
7 65 Graft failure B9 23 citrate 3 alive
8 50 NASH C12 36 nil 3 transplanted, alive
9 64 Alcoholic C13 34 nil 1 deceased
10 54 a1-AT deficiency C13 50 citrate 1 deceased
a1-AT deficiency, a1-antitrypsin deficiency; MELD, model for end-stage liver disease
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RRs, was higher during regional citrate anticoagulation
(Table 3). Total bilirubin RR with regional citrate antic-
oagulation (RR 0.25, SD 0.09) were significantly (P =
0.02) higher than without anticoagulation (RR 0.15, SD
0.10). A similar trend was seen for RRs of urea (P =
0.06) and creatinine (P = 0.10). These differences were
lost when looking at completed treatment sessions only.
Feasibility of citrate anticoagulation
We monitored adequacy and safety of regional citrate
anticoagulation during MARS treatment in patients with
acute-on-chronic liver failure. Ionized calcium concen-
tration targets (0.2 ≤ Ca2+ ≤ 0.3 mmol·l-1) at the MARS
dialyzer inlet were reached in all patients (Figure 3a).
Systemic ionized calcium concentrations (Figure 3b)
were significantly reduced during citrate anticoagulation
as compared to anticoagulation-free MARS sessions (P
< 0.001, at 30, 60, 120, 240 and 360 min). In two
patients, systemic ionized calcium concentrations
dropped below 0.8 mmol·l-1, triggering per protocol
bolus infusions of CaCl2. Overall, reductions in systemic
ionized calcium concentrations were modest and did
not result in clinical symptoms. Overall, ionized calcium
concentrations remained in the physiological range in
all patients at all time points.
In addition, we monitored the ratio of total blood
calcium to ionized calcium concentrations (Catot/Ca
2+).
As Catot represents the sum of ionized, protein-bound
and citrate-bound calcium, increased ratios are consid-
ered a marker of citrate accumulation. During three
sessions, we observed a ratio slightly exceeding 2.5. It
is important to notice that ratios returned to baseline
at the start of the next MARS session in all patients.
Acid-base status was similar at all individual time
points and did not significantly differ from sessions
without heparin, excluding massive accumulation of
citrate.
Discussion
We performed a prospective randomized controlled trial
on anticoagulation protocols during Molecular Adsorp-
tion Recirculating System (MARS) treatment. Regional
citrate anticoagulation of the extracorporeal circuit
under strict metabolic monitoring appears safe, feasible
and proves superior to MARS treatment without
anticoagulation.
Liver failure is a heterogeneous disease state resulting
from either acute or chronic relentless loss of liver syn-
thetic or detoxification function. To improve outcomes
of this grave condition, several experimental (bio-)artifi-
cial devices have been developed, including fractionated
plasma separation and adsorption (FPSA) and the mole-
cular adsorption and recirculating system (MARS) [2].
Patency of the extracorporeal blood circuit is a prerequi-
site for all of these therapies.
Anticoagulation using unfractionated heparin given to
maintain patency of the extracorporeal device exerts sys-
temic effects. This may tipple over a balanced but brittle
coagulation system such as seen in liver failure [3]
towards severe bleeding. On the contrary, insufficient
anticoagulation leads to contact activation during pas-
sage of the extracorporeal circuit, thereby inducing
Figure 2 Kaplan Meier estimate of events during MARS. Patients were grouped according to anticoagulation regimen during MARS
treatment. None of the patients receiving citrate anticoagulation developed an event necessitating preterm cessation of MARS treatment. Four
sessions without anticoagulation were interrupted preterm, one due to uncontrollable bleeding and three due to occlusive clotting of the
extracorporeal blood circuit. Log Rank P = 0.03. MARS, Molecular Adsorbents Recirculation System.
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clotting of the circuit and/or increasing the risk of
thrombosis after coagulation propagation.
Regional citrate anticoagulation might prove a valid
alternative. Citrate efficiently reduces extracorporeal cir-
cuit ionized calcium concentration, a necessary cofactor
for coagulation. Recalcification normalizes anticoagula-
tion prior to returning blood to the systemic circulation.
In hemodialysis patients, regional citrate anticoagulation
proves a valid alternative for unfractionated heparin and
low molecular weight heparins [11]. The downside of
regional citrate anticoagulation is that only part of the
used citrate is eliminated by the extracorporeal device,
whereas the other part is returned to the patient, the
amount of which depends on the extracorporeal device.
Citrate is metabolized by the liver and to a lesser extent
by other tissues, for example, the intestines and the
kidneys. While this appears safe in patients with end-
stage kidney disease, it has long been held that liver dys-
function and especially liver failure is a contra-indication
for use of regional citrate anticoagulation. Recently, sev-
eral observational studies suggest that citrate anticoagu-
lation can be safely used in patients with liver failure
treated with either FPSA or MARS [14,15]. In this
study, we confirm that regional citrate anticoagulation
for MARS is safe and feasible.
A critical aspect not touched upon previously is a
comparison between these anticoagulation strategies.
This is the first prospective randomized study to
demonstrate superior patency during MARS using regio-
nal citrate anticoagulation when compared to no antic-
oagulation. The primary endpoint was longevity of
prescribed MARS treatment sessions. Three out of 13
Table 3 Comparison of regional citrate anticoagulation versus anticoagulation-free MARS
Citrate No anticoagulation P
Primary endpoint
Completed sessions 14/14 9/13 0.04
Secondary endpoints
Clotting score dialyzer (n) 0.009
Clean, white 2 2
White, limited fibrin deposits, head of dialyzer 7 3
White, fibrin deposits head and body dialyzer 5 5
Completely clotted, rinse back successful 0 1
Completely clotted, rinse back unsuccessful 0 2
Platelets (x 103/mm3)
Start of treatment 112 (58 - 146) 92 (67 - 169) 0.6
End of treatment 85 (67 - 162) 89 (60 - 117) 0.7
Reduction of platelets (P intra-group) 12 (P 0.08) 28 (P 0.0005) 0.03
aPTT (s)
Start of treatment 44.1 (40.5 - 57.2) 57.8 (40.7 - 75.4) 0.5
End of treatment 48.0 (41.3 - 61.5) 52.5 (40.0 - 65.7) 0.6
PT (s)
Start of treatment 14.2 (13.8 - 16.0) 17.2 (14.6 - 22.0) 0.1
End of treatment 14.5 (14.0 - 16.2) 16.1 (13.8 - 18.3) 0.4
TAT complex (μg/L)
End of treatment 9.9 (7.7 - 91.7) 25.7 (19.5 - 40.5) 0.3
Increase during treatment 6.1 (5.1 - 50.1) 25.1 (16.8 - 40.5) 0.09
Treatment efficacy, all sessions
Urea reduction ratio 0.51 (0.14) 0.40 (0.14) 0.06
Creatinine reduction ratio 0.40 (0.13) 0.31 (0.17) 0.10
Bilirubin (total) reduction ratio 0.25 (0.09) 0.15 (0.10) 0.02
Bile acids reduction ratio 0.47 (0.20) 0.42 (0.16) 0.34
Treatment efficacy, completed sessions
Urea reduction ratio 0.51 (0.14) 0.46 (0.12) 0.4
Creatinine reduction ratio 0.40 (0.13) 0.40 (0.14) 0.9
Bilirubin (total) reduction ratio 0.25 (0.09) 0.18 (0.09) 0.1
Bile acids reduction ratio 0.47 (0.20) 0.46 (0.21) 0.9
aPTT (S), activated partial thromboplastin time (S); MARS, Molecular Adsorbents Recirculation System; PT, prothrombin time (S); TAT complex, thrombin
antithrombin complex.
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Figure 3 Parameters of citrate anticoagulation. (a) Extracorporeal ionized calcium concentrations (mmol·l-1) at the MARS dialyzer inlet during
regional citrate anticoagulation. (b) Systemic ionized calcium concentrations (mmol·l-1) in patients with regional citrate anticoagulation (closed
circles) and in patients receiving MARS treatment without additional anticoagulation (closed cubes). (c) Systemic pH in patients treated with
regional citrate anticoagulation. MARS, Molecular Adsorbents Recirculation System.
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MARS sessions performed without anticoagulation were
interrupted preterm due to occlusive clotting of the
extracorporeal circuit, in line with previous observations
(Table 1) [10]. In contrast, none of the treatment ses-
sions using regional citrate anticoagulation ended pre-
term (Log rank P = 0.03).
This translates in significantly higher RRs of total
bilirubin (P = 0.02) in patients when citrate anticoagula-
tion was used. When analyzing completed treatment
sessions only, RRs were similar. This suggests that
observed differences should predominantly be ascribed
to treatment downtime rather than to reduced perme-
ability of clotted dialysis fibers.
The current study has several limitations. Due to the
cross-over design all patients are treated with both
citrate anticoagulation and without anticoagulation. This
precludes between groups analysis of longer-term out-
comes. Second, the number of patients is small, increas-
ing the risk of type I error. Finally, liver failure is a
heterogeneous disease state. For all of these reasons we
opted for a cross-over design, where each patient is his/
her own control, thereby minimizing the effects of het-
erogeneity and increasing the statistical power. Never-
theless, while regional citrate anticoagulation provides
superior patency and increased treatment efficacy as
compared to no anticoagulation, the available metabolic
data need confirmation in a larger cohort of patients.
We do not have data on systemic citrate accumulation.
Observed ratios of total calcium over ionized calcium
ruled out important accumulation of citrate, thus reas-
suring safety of regional citrate anticoagulation during
MARS treatment. Nevertheless, continuous vigilance
when using citrate anticoagulation in patients with liver
failure is warranted, as these patients have a diminished
citrate clearance. An observation worth noticing is that
measurement of ionized calcium concentration might be
biased due to access recirculation. We, therefore, recom-
mend the use of a separate arterial line which, given the
setting of the patients, most often is in place.
Conclusions
Avoidance of anticoagulation during MARS results in
significant loss of treatment efficacy due to treatment
downtime. Regional citrate anticoagulation for MARS
treatment is feasible. The metabolic tolerance is good,
but continuous vigilance and strict metabolic monitor-
ing remains warranted. Additional studies are required
to identify the optimal anticoagulation regimen for
extracorporeal circulation in patients with liver failure.
Key messages
• Regional citrate anticoagulation under strict meta-
bolic monitoring is feasible in patients with liver fail-
ure treated with the MARS system.
• Avoidance of anticoagulation during MARS results
in significant loss of treatment efficacy due to treat-
ment downtime.
• Additional studies are required to identify the opti-
mal anticoagulation regimen for extracorporeal cir-
culation in patients with liver failure.
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